anastrozole + letrozole + pertuzumab + trastuzumab

This is a non-standard, multi-drug combination consisting of two aromatase inhibitors (anastrozole and letrozole) and two HER2-targeted monoclonal antibodies (pertuzumab and trastuzumab). - **Anastrozole** and **letrozole** are small molecule aromatase inhibitors that block the conversion of androgens to estrogens, thereby reducing estrogen levels. They are primarily used in hormone receptor-positive breast cancer as hormonal therapy. - **Pertuzumab** and **trastuzumab** are recombinant humanized monoclonal antibodies targeting the human epidermal growth factor receptor 2 (HER2). Both bind to different domains on HER2, inhibiting its signaling pathways, leading to reduced tumor cell proliferation. This dual blockade is standard for treating HER2-positive breast cancer in both early-stage/adjuvant/neoadjuvant settings as well as metastatic disease[1][3][5]. There is no evidence that this exact four-drug combination (anastrozole + letrozole + pertuzumab + trastuzumab) is approved or commonly used together; typically only one aromatase inhibitor would be combined with anti-HER2 therapy in clinical practice.